Decision-making strategies for reperfusion therapies: navigating through stroke trials gaps

Estratégias de decisão para terapias de reperfusão: navegando nas lacunas dos trials de AVC

Mateus Paquesse PELLEGRINO1, Felipe Borelli DEL GUERRA2, Iago Navas PERISSINOTTI3,4

Abstract
Despite there being a robust amount of literature and numerous randomized clinical trials regarding acute ischemic stroke treatment, the trials have not included some frequent controversial situations for which decision-making strategies are an urgent and unmet need in clinical practice. This article tries to summarize the current evidence about some selected situations (mechanical thrombectomy in low ASPECTS, low NIHSS with proximal occlusion, acute basilar occlusion, distal and medium vessel occlusion, among others), make suggestions on how to approach them in clinical practice and show what to expect in acute stroke research in the near future.

Keywords: Stroke; Ischemic Stroke; Thrombectomy; Mechanical Thrombolysis; Thrombolytic Therapy.

INTRODUCTION
Acute ischemic stroke treatment has been one of the neurology subjects with the most advances in recent years and with the greatest volume of evidence from well-designed randomized clinical trials and extensive guidelines. However, a multitude of not uncommon clinical scenarios have not been properly addressed in the trials and evidence-based guidance on how to manage reperfusion therapies in the hyperacute setting is still lacking in these situations. The objective of this article is to perform a review of the current evidence regarding reperfusion therapy in controversial scenarios and make suggestions that could help the decision-making process in some of these challenging situations.

Endovascular thrombectomy in low ASPECTS

Most of the clinical trials that have demonstrated endovascular thrombectomy’s (EVT) benefit in anterior circulation ischemic stroke used ASPECTS (Alberta stroke program early computed tomography score) to select patients and were selective, excluding patients with a score < 6 and presumably a greater core volume. Therefore, little data regarding this population is available from the studies included in the HERMES collaboration1.
Although the MR CLEAN trial did not use ASPECTS or ischemic core volume as an exclusion criterion, the median ASPECTS in the study was 9 (IQR 7-10), only 28 (3.6%) out of 496 patients had an ASPECTS < 5 and 120 (24.2%) < 8.

A pre-specified (but not registered) meta-analysis from the HERMES collaboration that used individual data from seven clinical trials showed a benefit for patients with ASPECTS 3-5, with 30/98 (31%) of EVT group patients achieving a modified Rankin Scale (mRS) of 0-2 at 90 days compared to 14/90 (16%) of the control group (adjusted OR 4.27 [1.62-11.25]), but no benefit for patients with ASPECTS 0-2. Despite the supposed benefit, thrombectomy yielded a greater risk of symptomatic intracranial hemorrhage (sICH), present in 14/95 (15%) of the EVT group and 3/87 (3%) of the control group of patients with ASPECTS 3-5 (OR 4.84 [1.27-27.03]). Similar results of efficacy and sICH were found within the group with initial involvement greater than one third of the middle cerebral artery territory1.

After more widespread adoption of stroke thrombectomy, several observational studies were performed trying to assess this matter and they mainly suggest that thrombectomy could confer a better functional outcome in three months compared to conservative management, with some studies also suggesting lower mortality and craniectomy rates. Despite that, some studies also showed augmented risk for symptomatic intracranial hemorrhage2-7. One retrospective analysis of the German stroke registry also suggested higher risk for sICH, as well as higher mortality in the EVT group and no difference in favorable outcomes. However, a significant effect regarding recanalization status was shown, with 15% of mTICI (modified Thrombolysis in Cerebral Infarction Scale) 0-2a achieving an mRS 0-2 at 90 days in patients with ASPECTS < 6 were performed, the first including 17 studies and 1,378 patients6, the second, nine studies and 1,196 patients10. Both suggested better functional outcomes at 90 days in the endovascular group compared to best medical management, with 30.1% of the EVT group achieving an mRS 0-2 versus 3.2% of the medical group (P=0.001) in the first study6 and 27.7% and 3.7% in the second study, respectively (P=0.001)10. Regarding sICH, they produced conflicting results, one suggesting lower odds in EVT group (20% vs 31.7%, P=0.05), while the other showed a trend towards higher rates (9.2% vs 5.5%, P=0.11)10. One of the meta-analyses produced some subgroup data, showing that patients younger than 70 had higher rates of mRS 0-2 compared to older patients (40.3% vs 16.2%) and that initial ASPECTS had a direct relation with 90-day mRS 0-2 (33.3% of ASPECTS 5, 22.1% of ASPECTS 4, 13.9% of ASPECTS 0-3). Despite these important findings, both meta-analyses had serious limitations: most of the included studies were retrospective, not randomized and several lacked a control group; heterogeneity was high for most studied outcomes; the definition of sICH was variable among studies; ASPECTS could be determined using magnetic resonance imaging (MRI) or computed tomography (CT) depending on the study.

Despite ASPECTS being used as a selection criterion in most trials and guidelines until now, its use has great limitations, as each of the 10 predefined areas have diverse volumes and eloquence and each point is deducted in a binary fashion, disregarding the infarcted volume within each region, the degree of hypodensity and the eloquence of unaffected areas within each ASPECTS region. Some studies have already showed that the correlation of ASPECTS and core volume is limited11 and the more focused analysis of eloquence and degree of involvement in each region might play an important role in functional outcome and treatment effect12.

A recent single center observational study showed that in patients with ASPECTS ≤ 5 and baseline infarct volumes ≤ 70 ml the outcome of mRS 0-2 at 90 days in patients submitted to EVT was 38.9% against 18.8% of patients with volumes > 70 ml (P=0.04 after adjusted multivariate analysis)13. A post-hoc analysis of a HERMES collaboration meta-analysis that included 177 patients with baseline large core (defined as 80-300 ml in diffusion-weighted MRI / CT-perfusion or ASPECTS ≤ 5) suggested that in patients with cores 80-130 ml or ASPECTS 4-5, thrombectomy was associated with functional improvement (OR 2.11 [95% CI, 1.08-4.09]), but that could not be demonstrated in patients with cores > 130 ml or ASPECTS ≤ 3 (OR 1.75 [95% CI, 0.62-4.89]), in which EVT was also associated with possible worsening of edema and greater midline shift in follow-up images14. Both studies, despite their limitations, reinforce the importance of evaluating volumes and not only ASPECTS in the treatment decision.

Probably the best piece of evidence until now is the recently published randomized clinical trial conducted in Japan (RESCUE-Japan LIMIT), which randomized 203 patients with ASPECTS 3-5 to receive EVT or best medical care within six hours after they were last known to be well or within 24 hours if there were no early changes in FLAIR (fluid-attenuated inversion recovery) images. Patients had to have at least 6 points in the NIHSS, a previous mRS ≤ 1, occlusion of internal carotid artery or M1 segment of middle cerebral artery. ASPECTS could be measured either with CT or DW-MRI. No relevant baseline disparities were seen between groups and in general the included patients consisted of moderate to severe strokes: median NIHSS of 22, median ASPECTS of 3, median infarct volume of 94 ml (IQR 66-152) in EVT group and 110 ml (IQR 74-140) in the medical care group. The primary outcome of mRS 0-3 at 90 days was achieved in 31.0% of the endovascular group and 12.7% in the medical care group (RR 2.43; 95% CI 1.35 to 4.37; P=0.002). Any intracranial hemorrhage within 48 hours was significantly higher in EVT group (58% vs 31.4% [RR 1.85, 95% CI 1.33–2.58, P<0.001]) and sICH was also numerically higher, although not statistically significant (9.0% vs 4.9% [RR 1.84, 95% CI 0.64–5.29, P=0.25]). The main limitations of the study are that treating physicians and patients could not be blinded, the population consisted only of Japanese patients, alteplase was used in a small percentage of patients (27%), the standard dose of alteplase used in Japan is 0.6 mg/kg and almost 90% of
ASPECTS were calculated using MRI, limiting the applicability of the results to ASPECTS calculated using CT\textsuperscript{15}.

Besides achieving reperfusion of potentially salvageable and eloquent areas, other mechanisms of possible benefit of EVT in large stroke patients might play an important role, such as diminishing associated cerebral edema\textsuperscript{14} and preserving vascular cells in the ischemic area, facilitating vascular and neural repair\textsuperscript{16}.

With the existing evidence, EVT in patients with ASPECTS 0-2 seems to be futile, but it might be a reasonable treatment option for patients with ASPECTS 3-5, especially in the following situations: ASPECTS measured using diffusion-weighted MRI, ASPECTS 4-5, ischemic core volume < 130 ml (even better if < 70 ml), younger age, less edema and spared eloquent areas in the baseline image. However, several controversies still remain: the augmented risk of hemorrhagic transformation; no consensus about the best image modality for optimal selection (CT, CT-perfusion, diffusion-weighted MRI or novel techniques to measure established edema as baseline Net Water Uptake\textsuperscript{17}); the cost-effectiveness of the treatment, especially in a resource limited setting; better definition of a cutoff volume or ASPECTS for which benefit would still be sustained; establish the role of area eloquence analysis, age, collateral circulation status, beyond other factors.

Several clinical trials of EVT in low ASPECTS/large core are ongoing, with more data expected to be added in the next months/years (Table 1).

**ENDOVASCULAR THROMBECTOMY FOR MEDIUM AND DISTAL VESSEL OCCLUSION**

Occlusion of the middle cerebral artery (MCA) after its first bifurcation (although not anatomically accurate, the majority of thrombectomy trials considered this as M2 segment, so we will use this same terminology in this article) was excluded from most EVT randomized clinical trials, as well as anterior cerebral artery (ACA) and posterior cerebral artery (PCA) occlusions. Some of the trials included M2 occlusions, but they were under-represented and were mainly proximal and dominant trunks, functionally similar to M1 occlusions\textsuperscript{18}.

Therefore, EVT for medium/distal vessels lacks support from studies with good evidence, despite the high prevalence of occlusion of these vessels in initial imaging (primary occlusions) accounting for 25-40% of strokes\textsuperscript{19} and also as a complication of large vessel occlusion treatment (secondary occlusion), either to the same territory of the initial large vessel (incomplete reperfusion was found in 80% of HERMES collaboration trials\textsuperscript{20} or to a new territory (9.4% of internal carotid artery (ICA)/MCA thrombectomy complications with ACA embolization)\textsuperscript{21}.

As opposed to what is expected from proximal (ICA/M1) occlusion, distal vessel involvement confers a great heterogeneity of clinical presentations, as different territories are considered (ACA, MCA or PCA) and even when the same artery is occluded in two patients, due to great anatomic variability of distal vessels and collateral circulation, the functional and clinical importance of the occlusion can be diverse.

The occlusion diagnosis can be inferred as a dot sign in CT or MRI susceptibility vessel sign, confirmed when a cutoff can be shown in CT/MRI angiography. These signs can be more easily identified in the more proximal segments (M2, P1, A1), but can be difficult to find in more distal vessels and when there is a trifurcation or other anatomic variability, situations in which perfusion imaging can greatly improve sensibility to 80-100%\textsuperscript{22}, as well as inform if the territory of the occluded artery is still viable. In the absence of perfusion imaging, a clinical deficit consistent with the occluded artery with a clinical/core (diffusion-weighted MRI) mismatch can also be indicative of viable tissue.

While smaller territories are at risk when compared to proximal occlusion (ICA/M1), a great proportion of patients remain functionally dependent (mRS >2): 60% of M2\textsuperscript{23}, 70% of P1 and 44% of P2 occlusions\textsuperscript{24}. ACA isolated occlusions were associated with 49% of patients moving to chronic care facilities or mRS >2\textsuperscript{25} and ACA embolization during ICA/M1 EVT conferred significant lower rates of 90-day mRS 0-2 (25% vs 48% [adjusted OR 0.48, 95% CI 0.25-0.92, P=0.027])\textsuperscript{13}. Early recanalization after intravenous thrombolysis, despite greater than for ICA/M1 occlusion, are unsatisfactory, being achieved only in 37-44% of M2\textsuperscript{26,27}, 52% of M2-M3\textsuperscript{28} and 42% of M3/ACA/PCA occlusions\textsuperscript{29}, justifying the study of alternative treatments, as EVT.

Due to greater distance, increased tortuosity and smaller diameters in more distal vessels, EVT poses more technical challenges and risks (dissection, perforation, vasospasm, embolization to new territories) when compared to proximal occlusions, but endovascular technology has advanced with smaller/low profile stent retrievers and aspiration catheters that are suitable for distal vessels\textsuperscript{30-32}.

The HERMES collaboration analyzed the data from 130 patients with M2 occlusion included in the pivotal EVT trials and found a TICI 2b-3 recanalization in 59.2% of patients and 90-day mRS 0-2 in 58.2% of EVT group against 39.7% in control group (adjusted OR 2.39 [95% CI 1.08-5.28, P=0.03]). Treatment effect favoring EVT was maximal in proximal and dominant M2 (adjusted OR of 2.68 and 4.08, respectively)\textsuperscript{33}. Thrombectomy with stent retrievers and aspiration catheters has shown comparable results for M2 occlusions in more recent studies, with a TICI 2b-3 recanalization rate above 80%\textsuperscript{34}.

Small (n=69 and 130) single center observational studies of EVT for M3-M4, ACA and PCA occlusions (distal MCA cases were majority) showed that the procedure is feasible and safe, with satisfactory recanalization in 75-83% of cases, with similar results between primary and secondary occlusions and relevant intraparenchymal bleeding in 7-8% of cases\textsuperscript{35,36}. In one of the studies, which used several techniques (stent-retriever in 54%, aspiration in 45% and intra-arterial recombinant tissue plasminogen activator [rtPA] in 52%), the rate of 90-day mRS 0-2 was 30% (38-54% for M3), but strokes were moderate/severe.
Table 1. Ongoing randomized clinical trials regarding main themes addressed in the article.

| Study               | Comparison                     | Estimated enrollment | Inclusion criteria                                                                 | Primary outcome                                      | Country/region                          | Estimated completion |
|---------------------|--------------------------------|----------------------|------------------------------------------------------------------------------------|------------------------------------------------------|-----------------------------------------|----------------------|
| **Low ASPECTS / Large Core** |                                |                      |                                                                                   |                                                      |                                        |                      |
| LASTE (NCT03811769) | Thrombectomy vs medical care   | 450                  | ASPECTS (CT or DWI) 0-5 if <80 years or 4-5 if ≥80 years; < 7h from LKW; ICA (isolated cervical occlusion excluded), M1 or M1-M2 occlusion | 180-day mRS shift analysis / 90-day mortality        | France                                  | Feb/2022              |
| SELECT-2 (NCT03876457) | Thrombectomy vs medical care   | 560                  | ASPECTS (CT) 3-5 and/or core volume ≥50 ml on CTP/DWI; < 24h from LKW; ICA or M1 occlusion | 90-day mRS shift analysis / 90-day mRS 0-2           | USA, Canada, Australia, New Zealand and Spain | Nov/2022              |
| TESLA (NCT03805308) | Thrombectomy vs medical care   | 300                  | ASPECTS (CT) 2-5, < 24h from LKW, ICA (cervical excluded) or M1 occlusion           | UW 90-day mRS                                       | USA                                     | Nov/2022              |
| ANGEL-ASPECT (NCT04551664) | Thrombectomy vs medical care   | 488                  | ASPECTS (CT) 3-5 or core volume 70-100 ml on CTP/DWI in patients with >6h or <6h and ASPECTS (CT) 0-2; > 24h from LKW; terminal ICA or M1 occlusion | 90-day mRS                                       | China                                   | Nov/2022              |
| TENSION (NCT03094715) | Thrombectomy vs medical care   | 665                  | ASPECTS 3-5 (CT or DWI); ≤ 12h from LKW; M1/ICA occlusion                          | 90-day mRS shift analysis                           | Europe and Canada                      | Sep/2024              |
| **Distal / medium vessel occlusion** |                                |                      |                                                                                   |                                                      |                                        |                      |
| DISCOUNT (NCT05030142) | Thrombectomy vs medical care   | 488                  | NIHSS ≥ 5; 6h from LKW; primary occlusion of distal M2, M3, P1, P2, P3, A1, A2 or A3 | 90-day mRS 0-2                                      | France                                  | Dec/2023              |
| DISTALS (NCT05152524) | Thrombectomy vs medical care   | 168                  | Perfusion lesion (CTP or MRP) ≥ 10 ml; core (CTP or DWI) ≤ 50% of perfusion lesion; NIHSS 4-24 or 2-24 if aphasia or hemianopia; <24h from LKW; disabling deficit; primary non-dominant M2, M3, ACA, PCA occlusion and vessel diameter ≥ 1.5 mm; not eligible for IVT | Successful reperfusion (CTP or MRP) and no sICH      | Not informed (sponsored by a USA location company) | Aug/2024              |
| DISTAL (NCT05029414) | Thrombectomy vs medical care   | 526                  | NIHSS ≥ 4 or disabling deficit; 6h from LKW or 6-24h from LKW if CT/CTP or DWI/FLAIR mismatch present; M2, M3-M4, A1, A2, A3, P1 or P2 occlusion | 90 day-mRS                                         | Switzerland                             | Dec/2024              |
| ESCAPE-MeVO (NCT05151172) | Thrombectomy vs medical care   | 530                  | ASPECTS ≥ 8; NIHSS > 5 or NIHSS 3-5 with disabling deficit; < 12h from LKW; M2-M3 or A2-A3 or P2-P3 occlusion; penumbra demonstrated by CTA/CT/clinical exam or CTP or MRP or DWI/MRA/clinical exam | 90-day mRS                                       | 50 sites, coordination center at University of Calgary | Aug/2024              |
Table 1. Cont.

| Study               | Comparison                      | Estimated enrollment | Inclusion criteria                                                                 | Primary outcome                  | Country/region | Estimated completion |
|---------------------|---------------------------------|----------------------|-------------------------------------------------------------------------------------|----------------------------------|----------------|---------------------|
| Vertobrobasilar occlusion |                                 |                      |                                                                                     |                                  |                |                     |
| BAOCHE (NCT02737189) | Thrombectomy vs medical care    | 318                  | pc-ASPECTS ≥ 6; NIHSS ≥ 6; 6-24h from LKW (isolated vertigo not considered); BA or intracranial VA occlusion | 90-day mRS 0-3                   | China          | December 2022       |
| ATTENTION (NCT04751708) | Thrombectomy vs medical care    | 342                  | pc-ASPECTS ≥ 6 (≥ 8 if ≥ 80 years); NIHSS ≥ 10; <12h from estimated time of BAO     | 90-day mRS 0-3                   | China          | May 2023            |
| POST-ETERNAL (NCT05105633) | TK 0.25 mg/kg vs tPA 0.9 mg/kg (+/- EVT) | 688                  | pc-ASPECTS ≥ 7; <24h from LKW; BA occlusion (partial or complete) 90-day mRS 0-1 or return to baseline mRS |                                  | Australia       | December 2026       |

Low NIHSS with proximal occlusion

| Study               | Comparison                      | Estimated enrollment | Inclusion criteria                                                                 | Primary outcome                  | Country/region | Estimated completion |
|---------------------|---------------------------------|----------------------|-------------------------------------------------------------------------------------|----------------------------------|----------------|---------------------|
| MOSTE (NCT03796468) | Thrombectomy vs medical care    | 824                  | ASPECTS ≥ 6; NIHSS ≤ 5; <24h from LKW; ICA, M1 or M1-M2 occlusion                  | 90-day mortality                 | France         | Feb/2022            |
| ENDOLLOW (NCT04167527) | Immediate thrombectomy vs Initial medical care | 200                  | ASPECTS ≥ 6; NIHSS ≤ 5; <8h from LKW; ICA, M1 or “M1-like” M2 occlusion            | 90-day mRS ordinal shift analysis and sICH | United States | Jan/2023            |

A1: indicates first segment of anterior cerebral artery; A2: second segment of anterior cerebral artery; A3: third segment of anterior cerebral artery; ASPECTS: Alberta stroke program early computed tomography score; BA: basilar artery; BAO: basilar artery occlusion; CT: non-contrast computed tomography; CTA: computed tomography angiography; CTP: computed tomography perfusion; DWI: diffusion-weighted magnetic resonance imaging; FLAIR: fluid-attenuated inversion recovery magnetic resonance imaging; ICA: internal carotid artery; IVT: intravenous thrombolysis; LKW: last known well; M1: first segment of middle cerebral artery; M2: second segment of middle cerebral artery; M3: third segment of middle cerebral artery; MRA: magnetic resonance angiography; MRP: perfusion magnetic resonance imaging; mRS: modified Rankin scale; NIHSS: National Institutes of Health Stroke Scale; P1: first segment of posterior cerebral artery; P2: second segment of posterior cerebral artery; P3: third segment of anterior cerebral artery; pc-ASPECTS: posterior circulation acute stroke prognosis early computed tomography score; sICH: symptomatic intracerebral hemorrhage; VA: vertebral artery.
with median baseline NIHSS of 18 (IQR 13-23) and mortality of 20%.

A multicenter case-control study of EVT for primary distal PCA (P2-P3) occlusion (TOPMOST) showed a mTICI 2b-3 recanalization rate in 87.4% of cases using several techniques (stent-retriever +/- aspiration in 72%, primary aspiration in 26% and intra-arterial rtPA in 14%). Among 184 matched patients, EVT conferred a non-significant better result in median NIHSS decrease at discharge (mean difference -1.5 [95% CI 3.2 to -0.8; P=0.06]), with significant results shown in subgroup analysis of NIHSS ≥ 10 (mean difference -5.6 [95% CI -10.9 to -0.2; P=0.04) and patients not submitted to intravenous rtPA (mean difference -3.0 [95% CI -5.0 to -0.9; P=0.005). Although the favorable results of NIHSS decrease at discharge, no difference was shown for 90-day mRS 0-2 (76.6% vs 75.4%; P=0.87). Regarding safety concerns, there was no difference in sICH (4.3% in both groups, P=0.99) or mortality (11.8% vs 15.8%, P=0.40). Median baseline NIHSS in this study was 5 (IQR 3-10).

Small (n=41 and 30) single center observational studies of EVT (83% with stent-retriever) for distal ACA occlusions also showed good mTICI 2b-3 rates (83-88%) and low rates of complications, with 10% of asymptomatic regional subarachnoidal bleed described in one series and 10% of vasospasm and 3.3% of asymptomatic hemorrhagic transformation in ACA territory in the other. Initial NIHSS was high (mean of 17-18) and 90-day mRS 0-2 was achieved in only 20-36% of patients, but almost all were associated with ICA/M1 occlusion, limiting the interpretation of these outcomes.

Although several studies indicate that thrombectomy for distal occlusion is safe and viable, only a few studies have compared its efficacy to intravenous rtPA. One meta-analysis of four retrospective observational studies (with significant heterogeneity [I²=89%]) with 381 patients with A2, M3-M4 or P2-P4 occlusion did not demonstrate a significant difference in 90-day mRS 0-2 between the groups (OR 1.16, 95% CI 0.23–5.93; P=0.861).

Currently there is very limited evidence, mainly from observational studies, regarding endovascular thrombectomy to distal and medium vessels occlusion, making it not possible to make general recommendations about its clinical effectiveness in comparison with best medical care. In selected cases, considering the relative safety and high recanalization rates of present-day endovascular techniques, a multi-specialty (stroke neurologist, neuroradiologist and neurointerventional radiologist) individualized approach could be sought, taking several factors into consideration: more proximal occlusions (A1, P1 and M2 - especially if the occluded M2 is dominant, for which there is some subgroup favorable data from randomized clinical trials), higher baseline NIHSS or disabling deficits, presence of relevant penumbra-core or clinical-core mismatch in eloquent locations, contraindication to intravenous thrombolysis (IVT) as factors in favor of EVT; and difficult proximal access, more tortuous vasculature, lower baseline NIHSS with no disabling deficits, greater proportion of core in the involved territory as factors against it. A lot of questions still need to be addressed, as the use of advanced imaging techniques in selection of patients; the role of intra-arterial rtPA, which was demonstrated to be safe and with some exciting good clinical results in a recent randomized trial suggesting the importance of distal circulation reperfusion; what the factors are for achieving a relevant treatment effect; among others. Despite the difficulty of designing randomized clinical trials due to great clinical heterogeneity, several are under way and some answers are expected in the future (Table 1).

**Acute Basilar Artery Occlusion**

Acute ischemic stroke due to basilar artery occlusion (BAO) represents 20% of posterior circulation strokes and 1-4% of all ischemic strokes. BAO is one of the most challenging emergencies with death rates up to 80-90% in the absence of therapeutic interventions. The clinical picture of BAO varies greatly, with 30-60% of patients presenting with coma, tetraplegia or locked-in syndrome. In the majority trials of stroke reperfusion, BAO and posterior circulation stroke are underrepresented. Optimal reperfusion strategies are still under discussion.

The Basilar Artery International Cooperation Study (BASICS) registry, an observational prospective multicenter study, reported a 10-19% absolute lower death rate and dependency for severe patients with acute BAO treated with intravenous thrombolysis (IVT) or EVT, compared to therapy with anti-platelet or anticoagulant drugs. Yet death ranged from 40% to 50% in patients submitted to IVT and EVT, with 6% of sICH in IVT group.

The reverse filling of the distal basilar artery by posterior communicating arteries and the abundant collaterals from posterior circulation collaborate to brainstem ischemic resistance. It has been suggested that as long as perforators are patent, brainstem can be viable for a long period. The small infarct cores compared with anterior circulation contribute to resistance to hemorrhagic transformation in the brainstem. Based on these hypotheses, IVT has been simultaneously or immediately followed by anticoagulation in BAO for more than 20 years by a group from Helsinki in patients up to 12 hours after the sudden onset of neurological deficits or up to 48 hours of progressive neurologic deficits. The Helsinki group reported that, in 207 patients treated with IVT and anticoagulation, favorable outcomes of mRS 0–3 were achieved in 41.1% and mRS 0-2 in 31.3% at three months. The recanalization rate was around 70% and sICH, 11.4%. However, there is no evidence based on randomized clinical trials that add-on anticoagulation is beneficial in acute BAO.

EVT has led to dramatic changes in anterior circulation stroke treatment and a meta-analysis of 45 studies and 2056 patients concluded that recanalization has a significant effect on BAO outcomes (number needed to treat of 2.5 to prevent death and disability). Rates of recanalization up to 80–100% can be achieved after EVT in BAO. Yet, no striking benefit has
been achieved in the latest randomized trials of EVT in BAO. Reasons that may justify this are the slow recruitment, lack of a criteria for patient selection such as in anterior circulation, lack of equipoise, as there are several reports of a favorable outcome with EVT in retrospective and observational trials, so physicians may consider it is not appropriate to randomize these patients anymore.

An open label, randomized trial (BEST) of EVT up to eight hours after the estimated onset of BAO was stopped prematurely due to a high crossover rate (22%) and drop in recruitment, probably due to loss of equipoise. The study’s primary endpoint analysis failed to show a difference in the proportion of patients with favorable neurologic outcomes (90-day mRS 0–3 of 42% in the intervention group vs 32% in controls [adjusted OR 1.74; 95% CI 0.81–3.74]) despite 71% achieving successful reperfusion. After accounting for the effects of crossover, there were higher rates of favorable outcome in patients who received intervention compared to control in the as-treated population, 47% vs 24% (adjusted OR 3.02; 95% CI 1.31–7.00). A higher incidence of sICH in the intervention group was documented (8% vs 0), however mortality was similar (33% in intervention vs 38% in control)47.

BASILAR, a nonrandomized study, suggested that EVT (n=647) may be safe and effective up to 24 hours after the estimated onset of BAO, when compared to control (n=182). EVT was associated with a significantly higher rate of 90-day mRS 0–3 (adjusted OR 4.70; 95% CI 2.53–8.75) and a lower mortality rate at 90 days (adjusted OR 2.93; 95% CI 1.95–4.40) despite an increase in sICH (7.1% vs 0.5%)48.

BASICS, a randomized trial of EVT up to six hours after the estimated onset of BAO, failed to demonstrate an overall benefit of EVT compared with control. The primary endpoint of favorable functional outcome (mRS 0–3) at 90 days was not significantly different between the groups of EVT (44.2%) and control (37.7%). In subgroup analysis, patients with NIHSS ≥10 had significantly more benefit if treated with EVT. EVT group sICH rate was 4.5%. The slight benefit of EVT in BASICS trial might be related to the overwhelming effect of IVT, administered to 80% of the patients and selection bias of patients to be randomized49. Comparisons between BASICS, BASILAR and BEST trials are limited by patient heterogeneity, differences in medical treatment (20–30% of EVT in BEST and BASILAR) and different time spans allowed for reperfusion. A Bayesian meta-analysis of both randomized trials and a patient-level meta-analysis of NIHSS ≥10 from both trials suggested significantly improved outcomes in the EVT arm49,50.

Relevant variables may influence BAO outcome. These are: onset time to treatment, age >60 years, higher NIHSS and Glasgow coma scale scores at admission, failure to recanalize and collateral circulation51–53. Embolic etiology may also be associated with worse outcomes. Nevertheless, higher recanalization rates have been reported with embolic occlusion than with in situ atherosclerotic thrombosis in BAO55. The site of occlusion also has prognostic implications when treated, and distal lesions have better outcomes than proximal ones56.

The extent of ischemia can be assessed with the posterior circulation acute stroke prognosis early CT score (pc-ASPECTS)57. Patients with pc-ASPECTS <8 typically have worse functional outcomes than those with higher scores, despite recanalization. However, others found that lower thresholds of pc-ASPECTS (≥5) are also associated with a good outcome58–60. In patients with pc-ASPECTS ≥8, the time to treatment may not influence outcomes61. In addition, in the ETIS study59, a time-dependent benefit was found in patients with pc-ASPECTS <8. In BASICS registry62, most of the benefit of reperfusion therapies was time-dependent, no severe patient after nine hours of estimated BAO achieved a favorable outcome. The pc-ASPECTS has been criticized by its interrater variability, need for expertise in scoring, and limitations of assessment of the posterior fossa on CT63.

Besides pc-ASPECTS, cerebellar infarct volume also seems to be an independent predictor for 90-day mortality. It is known that cerebellar mass effect due to infarction and edema may lead to hydrocephalus and brainstem compression. It is one of the important causes of death in acute BAO patients. In one study, risk of death was increased for baseline volume ≥4.7 ml64.

Collaterals and thrombus burden are an important predictor of clinical outcomes in anterior and posterior circulation strokes. BATMAN is a 10-point scoring system that includes these characteristics and is considered a predictor of functional outcome in BAO65. Higher BATMAN score means shorter thrombus and/or better collaterals. Reperfusion was associated with a good outcome in those with favorable BATMAN score (≥7), despite time to treatment <6 or > 6 hours. Yet, in patients with unfavorable BATMAN, time to treatment <6 hours was significantly related to good outcomes66.

There are many reports of patients with BAO, low pc-ASPECTS, long onset to treatment time (>24 hours) and severe presentation with favorable functional outcomes after reperfusion treatment and intensive rehabilitation. This is an additional dilemma for decision-making because despite a predicted unfavorable prognosis, some patients can achieve functional independence59,64. Therefore, physicians must be cautious with the self-fulfilling prophecy in BAO therapy decisions.

Therefore, against a life-threatening condition such as BAO, the best choice is an individualized therapy for each patient. Neurologists should decide on the type of treatment combination (IVT, EVT, add-on anticoagulation or no reperfusion therapy) based on clinical features (age, NIHSS, Glasgow Coma Scale), radiological appearance (infarct core, pc-ASPECTS, BATMAN, cerebellar infarct volume, site of occlusion), onset time to treatment, stroke mechanism and risk of sICH. The better the combination of these characteristics probably the better the outcome will probably be. If the combination of the variables does not seem favorable, most likely the recanalization will be futile.
The next studies in BAO should focus on how to adequately select patients who can have a substantial treatment effect and achieve good outcomes.

**PROXIMAL OCCLUSION WITH LOW NIHSS SCORES**

Patients with mild strokes can worsen after initial evaluation, mainly secondary to ischemic complications probably due to failure of collateral circulation and the presence of proximal occlusion is an independent predictor for this adverse scenario. Around 10% of patients with baseline NIHSS ≤ 6 have proximal occlusion detected on CT/MRI angiography and 20% have clinical deterioration ≥ 4 point on NIHSS, usually early after hospital arrival (median of 3.6h [IQR 1-16h]), causing worse functional outcomes. Therefore, these patients should be transferred for an EVT-capable center and closely monitored.

Thrombectomy trials included in HERMES collaboration included a small number of patients with NIHSS ≤ 10 and subgroup analysis for this population was not powered to show benefits from EVT. Until now, there are no randomized trials on this topic and observational evidence is divergent.

Some multicenter observational studies found no difference in functional outcomes between EVT group and best medical care group, with a higher risk of sICH in EVT group. However, in these studies, there was no differentiation if patients received immediate EVT on admission or rescue EVT (performed only after clinical deterioration); both were included in the EVT group and the prognosis of patients that have clinical deterioration is known to be worse. In the studies in which IVT to EVT time was available, median time was much longer than would be expected. In a planned randomized trial, patients that received initial medical care followed by rescue EVT would be considered as being part of the medical care group.

A multicenter retrospective study considered this important factor in its analysis, including 80 patients in the immediate EVT group and 220 patients in the medical care group, of which 25 (11.3%) received rescue EVT. Immediate EVT was an independent predictor of mRS 0-2 (OR 3.1, 95% CI 1.4–6.9) with an absolute difference of 15% (85% vs 70%), but conferred not statistically significant higher rates of sICH (5% vs 1.4%, P=0.08). Matched analysis corroborated the results, with higher rates of 90-day mRS 0-2 in the immediate EVT group (84.4% vs 70.1%, P=0.03) and not statistically significant higher numbers of sICH (5.2% vs 2.6%, P=0.41).

Despite current guidelines recommending against IVT in minor non-disabling strokes, this recommendation was mainly based on the results of the PRISMS trial, in which the rate of proximal occlusion was a minority. Therefore, due to the increased risk of stroke progression in the patients with proximal occlusion, IVT should still be considered.

A recent multicenter retrospective French study with 729 patients with large vessel occlusion and NIHSS <6 that were treated with IVT showed that still after IVT ischemic early neurological deterioration occurred in 12% of patients and was strongly associated with poorer 90-day outcomes, even in patients who underwent rescue thrombectomy. This cohort was used to elaborate a novel 4-point score for early ischemic neurological deterioration prediction using the two factors that were independently associated with it in multivariable analysis: a more proximal occlusion site (0 point for M2; 1 point for distal M1; 2 points for proximal M1 or tandem or basilar; 3 points for terminal ICA) and longer thrombus (1 point if ≥ 9mm). The score was validated in another cohort and showed good discriminative power. In both cohorts early deterioration probability was approximately 3%, 7%, 20%, and 35% for scores of 0, 1, 2 and 3-4, respectively.

While the results of two ongoing randomized clinical trials are expected in the next year to better guide reperfusion therapies (Table 1), in conjunction with the imaging features of the aforementioned score, some clinical information that possibly indicates an unstable collateral circulation with higher risk of imminent failure can be used to help in making clinical decisions, such as deficit fluctuation, auto-hypertension and a stress test consisting of sitting the patient upright for 10-20 minutes or even walking and observing for signs of clinical deterioration. Some clinicians may also pursue surrogate measures of vascular reserve such as transcranial doppler ultrasound or perform perfusion imaging to demonstrate a possible territory at risk. Although biologically plausible, all these alternatives lack proper validation.

**INTRAVENOUS THROMBOLYSIS IN PATIENTS USING DOACS**

In the last few years, there has been an increase in the number of patients taking direct oral anticoagulants (DOACs). The American Heart Association guidelines recommend against IVT in patients who have taken DOACs in the last 48 hours. However, there have been successful case reports of patients receiving IVT after reversal of dabigatran by idarucizumab. Other reversal agents such as andexanet alpha have potential prothrombotic effects, but its reversal effects are known to be less reliable, and the evidence is even scarcer. A meta-analysis (with no heterogeneity, P=0) of patients taking DOACs (n=366) that received IVT found no difference in sICH compared to patients taking warfarin with international normalized ratio < 1.7 (n=2133) or patients without prior anticoagulation (n=50324). In addition, last DOAC intake time and use of pre-thrombolysis idarucizumab were not related with sICH. However, randomized trials are still lacking and are not expected soon. Unaltered drug-specific coagulation assays or thromboelastography could serve as a surrogate for low DOAC activity and confer a better safety profile for thrombolysis, but these are not readily accessible in a timely manner in most hospitals, validation for this use has yet to be reported and patients with altered results would still be excluded from treatment.

Factors that could counterbalance in favor of administering IVT would be a severe/debilitating presentation, possibility...
of IVT in the first hours when benefit is maximal, absence of other conditions that increase sICH risk, longer time from last DOAC administration and normal drug-specific assays/thromboelastography. In patients with minor stroke, EVT indication (where IVT bridging efficacy is under debate), high risk for sICH, >3h from last known well and very recent use of DOAC, the risks would probably outweigh the benefits of IVT. Further studies are urgently needed to access whether previous DOAC use should be withheld as a contraindication in current guidelines, as has occurred with several previous IVT contraindications. The development of more accessible point of care coagulation tests for better selection of patients might also be a useful strategy in the near future75.

ENDOVASCULAR THROMBECTOMY AFTER 24 HOURS OF TIME LAST KNOWN WELL

EVT up to 24 hours had a huge effect and shifted the traditional time window to tissue-based evaluation for patient selection. A retrospective multicenter series demonstrated similar outcomes in patients treated with more than 24 hours from time last known well that otherwise met DAWN76 criteria in comparison with patients in DAWN trial intervention group regarding mTICI 2b–3 (81% vs 84%, P=0.72), 90-day mRS 0–2 (43% vs 48%, P=0.68) and sICH (5% vs 6%, P=0.87). Median interval from time last known well to groin puncture was 48 hours (IQR 30-72h)77. Another retrospective series of patients with more than 16 hours from time last known well (median of 43.5h [IQR 23-77h]) where EVT was indicated at the discretion of the clinician (n=24) showed favorable outcomes when compared to a propensity score-matched data set with a higher proportion of 90-day mRS 0-2 (adjusted OR 11.08 [95% CI 1.88-108.60]). Although not statistically significant, DEFUSE-3 imaging criteria might have the potential to determine which patients benefit from treatment79.

There are probably few patients who are ultra-slow progressors due to enhanced collateral circulation that still can benefit from EVT. Therefore, reperfusion strategies might be considered as a possibility even in patients beyond 24 hours of time last known well with small infarct core at presentation and who would otherwise be included in DAWN or DEFUSE-3 criteria.

In conclusion, the strong evidence in favor of reperfusion therapies in the management of acute ischemic stroke and its relevant impact on functional outcomes for some already established situations have led to research as to whether other, not yet still well-studied stroke populations could also greatly benefit from it. Fortunately, stroke research keeps progressing with outstanding multicenter and coordinated efforts to advance the boundaries of current knowledge, with exciting new data expected in the near future (Table 1).

ACKNOWLEDGMENTS

We thank Dr. Fausto Motta Ferraz (Instituto de Radiologia – InRad, Hospital das Clínicas da FMUSP) for comments on the manuscript.

References

1. Goyal M, Menon BK, van Zwam WH, Dippel DWJ, Mitchell PJ, Demchuk AM, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016 Apr 23;387(10029):1723-31. https://doi.org/10.1016/S0140-6736(16)00163-X
2. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, et al. A randomized trial of intraarterial treatment for acute ischemic stroke. N Engl J Med. 2015 Jan 1;372(1):11-20. https://doi.org/10.1056/NEJMoai141587
3. Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoe CBLM, et al. Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data. Lancet Neurol. 2018 Oct 1;17(10):P985-904. https://doi.org/10.1016/S1474-4422(18)30244-4
4. Mourand I, Abergel E, Mantilla D, Ayrgyzan X, Sacagiu T, Eker OF, et al. Favorable revascularization therapy in patients with ASPECTS ≤5 on DWI in anterior circulation stroke. J Neurointerv Surg. 2018 Jan;10(1):5-9. https://doi.org/10.1136/neurintsurg-2017-013358
5. Broocks G, Hanning U, Flottmann F, Schönfeld M, Fei A-H, Gao C-J, et al. Clinical benefit of thrombectomy in stroke patients with low ASPECTS is mediated by oedema reduction. Brain. 2019 May 1;142(5):1399-407. https://doi.org/10.1093/brain/awz2057
6. Desilles JP, Consoli A, Redjem H, Coskun O, Cicció G, Smajda S, et al. Successful reperfusion with mechanical thrombectomy is associated with reduced disability and mortality in patients with pretreatment diffusion-weighted imaging-alberta stroke program early computed tomography score ≤8. Stroke. 2017 Apr;48(4):963-69. https://doi.org/10.1161/STROKEAHA.116.015202
7. Jiang S, Peng Y, Jing C-H, Fei A-H, Wang H-R, Gao C-J, et al. Endovascular thrombectomy can be beneficial to acute ischemic stroke patients with large infarcts. J Neurosurg. 2018 May 1;130(4):1383-90. https://doi.org/10.3171/2017.11.JNS171297
8. Meyer L, Bechstein M, Bester M, Hanning U, Brekenfeld C, Flottmann F, et al. Thrombectomy in extensive stroke may not be beneficial and is associated with increased risk for hemorrhage. Stroke. 2021 Oct;52(10):3109-17. https://doi.org/10.1161/STROKEAHA.120.033101
9. Cagnazzo F, Derraz I, Dargazani C, Lefèvre Ph, Gascou G, Riquelme C, et al. Mechanical thrombectomy in patients with acute ischemic stroke and ASPECTS ≤6: a meta-analysis. J Neurinterv Surg, 2020 Apr;12(4):350-55. https://doi.org/10.1136/neurintsurg-2019-015237
10. Dietro JD, Dmytriw AA, Broocks G, Chen K, Hirsch JA, Kemmling A, et al. Endovascular thrombectomy for low ASPECTS large vessel occlusion ischemic stroke: a systematic review and meta-analysis. Can J Neurol Sci. 2020 Sep;47(5):612-9. https://doi.org/10.1017/cjn.2020.71
11. Haussen DC, Dehkharghani S, Rangaraju S, Rebello LC, Bouallama M, Grossberg JA, et al. Automated CT perfusion ischemic core volume and noncontrast CT ASPECTS (Alberta Stroke Program Early CT Score): correlation and clinical outcome prediction in large vessel stroke. Stroke. 2016 Sep;47(9):2318-22. https://doi.org/10.1161/STROKEAHA.116.014117
12. Kerleroux B, Benazkoun J, Janot K, Dargazanli C, Eraya DD, Benhassen W, et al. Relevance of brain regions' eloquence assessment in patients with a large ischemic core treated with mechanical thrombectomy. Neurology. 2021 Nov 16;97(20):e1975-85. https://doi.org/10.1212/WNL.0000000000012863

13. Bouslama M, Barreira CM, Haussen DC, Rodrigues GM, Pisani L, Frankel MR, et al. Endovascular reperfusion outcomes in patients with a stroke and low ASPECTS is highly dependent on baseline infarct volumes. J Neurointerv Surg. 2022 Feb;14(2):117-21. https://doi.org/10.1136/neurintsurg-2020-017184

14. Ng FC, Yassi N, Sharma Q, Brown SB, Goyal M, Majoie CBLM, et al. Cerebral edema in patients with large hemispheric infarct undergoing reperfusion treatment: a HERMES meta-analysis. Stroke. 2021 Nov;52(11):3450-8. https://doi.org/10.1161/JHEaro.2020.032348

15. Yoshiura S, Sakai N, Yamagami H, Uchida K, Beppu M, Toyoda K, et al. Endovascular therapy for acute stroke with a large ischemic region. N Engl J Med. 2022 Apr 7;386(14):1303-13. https://doi.org/10.1056/NEJMoas2118191

16. Tanaka Y, Nakagomi N, Doe N, Nakano-Doi A, Sawano T, Takagi T, et al. Early reperfusion following ischemic stroke provides beneficial effects, even after lethal ischemia with mature neural cell death. Cells. 2020 Jun 1;9(6):1274. https://doi.org/10.3390/cells9061274

17. Broocks G, Meyer L, McDonough R, Bechstein M, Hanning U, Fiehler J, et al. The benefit of thrombectomy in patients with low ASPECTS is a matter of shades of gray—what current trials may have missed. Front Neurol. 2022 Jan 14;12:719046. https://doi.org/10.3389/fneur.2021.719046

18. Menon BK, Hill MD, Davalos A, Roos YBWEM, Campbell BCV, Bendszus M, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke. 2007 Mar;38(3):948-54. https://doi.org/10.1161/01.STR.0000257304.21967.2a

19. Seners P, Turc G, Maier B, Mas J-L, Oppenheim C, Baron J-C. Incidence and predictors of early recanalization after intravenous thrombolysis: a systematic review and meta-analysis. Stroke. 2016 Sep;47(9):2409-12. https://doi.org/10.1161/STROKEAHA.116.014181

20. Kühn AL, Waklho AK, Lozano JD, Massari F, Rodrigues KDM, Marosfoi M, et al. Two-year single-center experience with the ‘Baby Trevo’ stent retriever for mechanical thrombectomy in acute ischemic stroke. J Neurointerv Surg. 2017 Jun;9(6):S41-6. https://doi.org/10.1136/neurintsurg-2016-012454

21. Altenbernd J, Kuhnt O, Hennigs S, Hilker R, Loehr C. Frontline ADAPT therapy to treat patients with symptomatic M2 and M3 occlusions in acute ischemic stroke: initial experience with the Penumbra ACE and 3MAX reperfusion system. J Neurointerv Surg. 2018 May;10(5):434-9. https://doi.org/10.1136/neurintsurg-2017-013233

22. Pfaff J, Herweh C, Pham M, Sibert C, Pfaff J, Herweh C, Pham M, Sibert C, Reinkensmeyer DJ, et al. Mechanical thrombectomy of distal middle cerebral artery occlusions in acute ischemic stroke: meta-analysis. Neurointervention. 2018 Sep;13(2):100-9. https://doi.org/10.5469/neurint.2018.000997

23. Grossberg JA, Rebello LC, Haussen DC, Bouslama M, Bowen M, Barreira CM, et al. Beyond large vessel occlusion strokes: distal occlusion thrombectomy. Stroke. 2018 Jul 1;49(7):1662-8. https://doi.org/10.1161/STROKEAHA.118.020567

24. Rikhtegar R, Mosimann PJ, Weber R, Wallocha M, Yamac E, Mirza-Aghazadeh-Attari M, et al. Effectiveness of very low profile thrombectomy device in primary distal medium vessel occlusion, as rescue therapy after incomplete proximal recanalization or following iatrogenic thromboembolic events. J Neurointerv Surg. 2021 Dec;13(12):1067-72. https://doi.org/10.1136/neurintsurg-2020-017035

25. Meyer L, Stracke CP, Jungi W, Wallocha M, Grosveld FB, et al. Thrombectomy for primary distal posterior cerebral artery occlusion stroke: the TOPMOST Study. JAMA Neurol. 2021 Apr 1;78(4):434-44. https://doi.org/10.1001/jamaneurol.2021.0001

26. Miszczuk M, Klein JF, Riegler C, Buehrer G, Siebert E. Mechanical thrombectomy of acute occlusions of individual distal anterior cerebral artery branches. J Clin Neurosci. 2022 Apr 1;98:P137-41. https://doi.org/10.1016/j.jocn.2022.02.003

27. Pfaff J, Herweh C, Pham M, Sibert C, Ringleb PA, Bendszus M, et al. Mechanical thrombectomy of distal occlusions in the anterior cerebral artery: recanalization rates, periprocedural complications, and clinical outcome. AJNR Am J Neuroradiol. 2016 Apr;37(4):673-8. https://doi.org/10.3174/ajnr.A4594

28. Waqs M, Kuo CC, Dossani RH, Monteiro A, Baig AA, Alkhaldi M, et al. Mechanical thrombectomy versus intravenous thrombolysis for distal large-vessel occlusion: a systematic review and meta-analysis of observational studies. Neurosurg Focus. 2021 Jul;51(1):E6. https://doi.org/10.3171/2021.4.FOCUS21139

29. Anadani M, Ajinkya S, Ateieh A, Vargas J, Chatterjee J, Turk A, et al. Intra-arterial tissue plasminogen activator is a safe rescue therapy with mechanical thrombectomy. World Neurosurg. 2019 Mar;123:e604-8. https://doi.org/10.1016/j.wneu.2018.11.232

30. Renú A, Millán M, San Román L, Blasco J, Martí-Fàbregas J, Terceño E. Incidence of arterial ischemic stroke: the CHANCE randomized clinical trial. JAMA. 2022 Mar 1;327(9):826-35. https://doi.org/10.1001/jama.2022.1645
56. Deguchi I, Osada T, Kimura H, Hayashi T, Takahashi S, Takao M. Clinical outcomes of mechanical thrombectomy following intravenous administration of recombinant tissue-type plasminogen activator for basilar artery occlusion. Clin Neurol Neurosurg. 2020 Jul;194:105796. https://doi.org/10.1016/j.clineuro.2020.105796

57. Puetz V, Sylaja PN, Coutts SB, Hill MD, Dzialoszinski I, Mueller P, et al. Extent of hypoattenuation on CT angiography source images predicts functional outcome in patients with basilar artery occlusion. Stroke. 2006 Sep;39(9):2485-90. https://doi.org/10.1161/STROKEAHA.107.511162

58. Kim JG, Lee D, Choi JC, Song Y, Lee DH, Suh DC. DWI-pc-ASPECT score in basilar artery occlusion: is 6 points or less always indicative of a bad outcome? Interv Neuroradiol. 2019 Aug;25(4):371-9. https://doi.org/10.1177/191919831872505

59. Guillaume M, Lapergue B, Gory B, Labreuche J, Consoli A, Mione G, et al. Rapid successful reperfusion of basilar artery occlusion strokes with pretreatment diffusion-weighted imaging posterior circulation ASPECTS <8 is associated with good outcome. J Am Heart Assoc. 2019 May 21;8(10):e010962. https://doi.org/10.1161/JAHA.119.010962

60. Sang H, Li F, Yuan J, Liu S, Luo W, Chen Z, Zhu Q, et al. Values of baseline posterior circulation acute stroke prognosis early computed tomography score for treatment decision of acute basilar artery occlusion. Stroke. 2021 Mar;52(3):811-20. https://doi.org/10.1161/STROKEAHA.120.031371

61. Mourad I, Mahmoudi M, Dargazanli C, Pavillard F, Arquicau Z, Labreuche J, et al. DWI cerebellar infarct volume as predictor of outcomes after endovascular treatment of acute basilar artery occlusion. J Neurinterv Surg. 2021 Nov;13(11):995-1001. https://doi.org/10.1136/neurintsurg-2020-016810

62. Yang H, Ma N, Liu L, Gao F, Mo D, Miao Z. The basilar artery on computed tomography angiography score for acute basilar artery occlusion treated with mechanical thrombectomy. J Stroke Cerebrovasc Dis. 2018 Jun;17(6):P1570-4. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.01.007

63. Tomyntz ND, Holm MB, Horowitz MB, Wechsler LR, Raina K, Gupta R, et al. Extensive brainstem ischemia on neuroimaging does not preclude meaningful recovery from locked-in syndrome: two cases of endovascularly managed basilar thrombosis. J Neuroimaging. 2008 Jan;18(1):15-7. https://doi.org/10.1111/j.1552-6569.2007.00147.x

64. Haussen DC, Oliveira RA, Patel V, Nogueira RG, Functional independence following endovascular treatment for basilar artery occlusion despite extensive bilateral pontine infarcts on diffusion-weighted imaging: refuting a self-fulfilling prophecy. Interv Neurol. 2016 Sep;3(3-4):179-84. https://doi.org/10.1136/neurintsurg-2020-016804

65. Kim J-T, Park M-S, Chang J, Lee JS, Choi K-H, Cho K-H. Proximal arterial occlusion in acute ischemic stroke with low NIHSS scores should not be considered as mild stroke. PLoS One. 2013 Aug 16;8(8):e70996. https://doi.org/10.1371/journal.pone.0070996

66. Saleem Y, Nogueira RG, Rodrigues GM, Kim S, Sharashidze V, Frankel M, et al. Acute neurological deterioration in large vessel arterial occlusion in acute ischemic stroke with low NIHSS scores and mild symptoms managed medically. Stroke. 2020 May;51(5):1428-34. https://doi.org/10.1161/STROKEAHA.119.027011

67. Sarraj A, Hassan A, Savitz SI, Grotta JC, Cai C, Parsha KN, et al. Endovascular thrombectomy for mild strokes: how low should we go? Stroke. 2018 Oct;49(10):2398-405. https://doi.org/10.1161/STROKEAHA.118.022114

68. Volny O, Zerna C, Tomek A, Bar M, Rocek M, Padr R, et al. Thrombectomy vs medical management in low NIHSS acute anterior circulation stroke. Neurology. 2020 Dec 15;95(24):e3364-72. https://doi.org/10.1212/01.wnl.0000000000010955

69. Nagel S, Bouslama M, Krause LU, Kupper C, Messer M, Petersen M, et al. Mechanical thrombectomy in patients with milder strokes and large vessel occlusions. Stroke. 2018 Oct;49(10):2391-7. https://doi.org/10.1161/STROKEAHA.118.021196
70. Khatri P, Kleindorfer DO, Devlin T, Sawyer RN Jr, Starr M, Mejilla J, et al. Effect of alteplase vs aspirin on functional outcome for patients with acute ischemic stroke and minor nondisabling neurologic deficits: the PRISMS randomized clinical trial. JAMA. 2018 Jul 10;320(2):156-66. https://doi.org/10.1001/jama.2018.8496

71. Seners P, Ben Hassen W, Lapergue B, Arquizan C, Heldner MR, Henon H, et al. Prediction of early neurological deterioration in individuals with minor stroke and large vessel occlusion intended for intravenous thrombolysis alone. JAMA Neurol. 2021 Mar 1;78(3):321-8. https://doi.org/10.1001/jamaneurol.2020.4557

72. Blogging Stroke [Internet]. Author Interview: Dr. Raul Nogueira, MD, on “Mechanical thrombectomy in patients with milder strokes and large vessel occlusions”. Stroke; 2018 [cited 2022 Mar 13]. Available from: https://journals.heart.org/bloggingstroke/2019/03/25/author-interview-dr-raul-nogueira-md-on-mechanical-thrombectomy-in-patients-with-milder-strokes-and-large-vessel-occlusions/

73. Berrouschot J, Stoll A, Hogh T, Eschenfelder CC. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke. 2016 Jul;47(7):1936-8. https://doi.org/10.1161/STROKEAHA.116.013550

74. Shahjouei S, Tsivgoulis G, Goyal N, Sadighi A, Mowla A, Wang M, et al. Safety of intravenous thrombolysis among patients taking direct oral anticoagulants: a systematic review and meta-analysis. Stroke. 2020 Feb;51(2):533-41. https://doi.org/10.1161/STROKEAHA.119.026426

75. Seiffge DJ, Wilson D, Wu TY-H. Administering thrombolysis for acute ischemic stroke in patients taking direct oral anticoagulants: to treat or how to treat. JAMA Neurol. 2021 May 1;78(5):515-6. https://doi.org/10.1001/jamaneurol.2021.0287

76. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, et al. Thrombectomy 6 to 24 Hours after stroke with a mismatch between deficit and infarct. N Engl J Med. 2018 Jan 4;378(1):11-21. https://doi.org/10.1056/NEJMoa1708442

77. Desai SM, Haussen DC, Aghaebrahim A, Al-Bayati AR, Santos R, Nogueira RG, et al. Thrombectomy 24 hours after stroke: beyond DAWN. J Neurointerv Surg. 2018 Nov;10(11):1039-42. https://doi.org/10.1136/neurintsurg-2018-013923

78. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018 Feb 22;378(8):708-18. https://doi.org/10.1056/NEJMoa1713973

79. Kim BJ, Menon BK, Kim JY, Shin DW, Baik SH, Jung C, et al. Endovascular treatment after stroke due to large vessel occlusion for patients presenting very late from time last known well. JAMA Neurol. 2020 Aug 10;77(1):21-9. https://doi.org/10.1001/jamaneurol.2020.2804

80. NIH – U.S. National Library of Medicine [Internet]. ClinicalTrials.gov. [cited 2022 Mar 7]. Available from: https://clinicaltrials.gov/